Avantor Performance degli utili passati
Criteri Il passato verificati 0/6
Gli utili di Avantor sono diminuiti a un tasso medio annuo di -20.9%, mentre il settore Life Sciences ha visto gli utili diminuire a un tasso medio annuo di 2.1%. I ricavi sono cresciuti diminuire a un tasso medio annuo di 2.4%.
Informazioni chiave
-20.89%
Tasso di crescita degli utili
-23.06%
Tasso di crescita dell'EPS
| Life Sciences Crescita del settore | 21.51% |
| Tasso di crescita dei ricavi | -2.35% |
| Rendimento del capitale proprio | -9.87% |
| Margine netto | -8.42% |
| Ultimo aggiornamento sugli utili | 31 Mar 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
AVTR: Reset Expectations And Execution Progress May Support Future Upside
Avantor's updated analyst price target moves lower by several dollars to reflect a reset in fair value to $9.92, as analysts reference reduced price targets across the Street and ongoing questions around market share trends and management execution. Analyst Commentary Recent Street research around Avantor clusters around lower price targets and a downgrade in rating, with most comments focused on valuation reset, market share questions, and confidence in management execution.Avantor Q1 2026 Earnings Review: Stabilization Emerging, But Recovery Not Yet Visible
Apr 30
AVTR: Expanded Quality Control Capabilities Will Support Execution Turnaround And Future Share Repricing
Analysts have trimmed their average price targets on Avantor, and the updated fair value estimate now stands at about $16.47. This reflects a softer sentiment around the stock as research notes point to share losses, reduced investment, and questions about management's ability to stabilize the business.AVTR: Reset Expectations And Share Repurchases May Support Future Upside
The analyst price target for Avantor has shifted lower to reflect a series of Street target cuts, including a move to $8.50. This change stems from concerns about share losses, constrained investment, and uncertainty over whether management can stabilize the business.AVTR: Execution Turnaround In Core Franchise Will Drive Future Share Repricing
Analysts have lowered their price targets on Avantor, with the updated fair value estimate moving from about $17.68 to $16.13 as they factor in concerns about share losses, underinvestment, and uncertainty around management's ability to stabilize the business, along with a higher assumed discount rate and P/E multiple. Analyst Commentary Recent Street research has tilted cautious on Avantor, highlighted by a downgrade to Underweight with a US$8.50 price target and several cuts to prior price targets.AVTR: Reset Expectations And Buybacks Will Support Future Upside Potential
Analysts have cut their average price target on Avantor by a few dollars to reflect lower fair value estimates, softer assumed revenue growth and profit margins, and a higher future P/E multiple in light of recent broad target reductions from firms across the Street. Several have moved targets in a $2 to $4 range, and one reset its view from $14 to $12.The Market Doesn't Like What It Sees From Avantor, Inc.'s (NYSE:AVTR) Revenues Yet As Shares Tumble 27%
Feb 13
AVTR: Service Expansion And Execution Will Drive Upside From Reset Expectations
Narrative Update: Avantor Analyst Price Target Shift Analysts recently trimmed their price target on Avantor to $12 from $14. This reflects updated views on the life science tools sector and a Q4 outlook where many companies have already set softer expectations for 2026.AVTR: Share Repurchases And Execution Risks Will Shape Turnaround Visibility
Analysts have trimmed their price target on Avantor by about $0.60, reflecting more cautious assumptions on revenue growth and future P/E. This is partly offset by slightly higher profit margin expectations and a marginally lower discount rate.AVTR: Execution Turnaround And Review Process Will Unlock Share Repricing Potential
Avantor's analyst price targets and fair value estimates have inched higher to around $17.68 per share. At the same time, lower assumed revenue growth, a higher discount rate, a reduced future P/E, and sharply higher profit margin expectations reflect analysts' mixed views following recent downgrades and concerns about execution and visibility.AVTR: Share Repurchases Will Drive Upside As Turnaround Visibility Improves
Analysts have modestly lowered their price targets on Avantor by a few dollars per share, generally to the low to mid teens in dollar terms. They cite reduced guidance, weaker quarters and limited visibility around the company’s turnaround and strategic review.AVTR: Share Repurchase Initiative And Execution Will Shape Recovery Prospects Ahead
Analysts have lowered their price target for Avantor from $14 to $12 per share, citing a weak quarter, reduced guidance, and ongoing execution risks as primary concerns behind the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets ahead of quarterly results, reflecting improved confidence in Avantor’s long-term positioning despite current volatility.AVTR: Share Repurchase And Execution Will Define Turnaround Prospects In 2025
Avantor’s analyst price target has decreased from $13.80 to $13.64. Analysts cite reduced company guidance, execution risks, and ongoing uncertainty surrounding its earnings outlook as key factors driving the revision.Avantor, Inc. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
Nov 01AVTR: Activist Pressure And Business Overhaul Will Drive Share Recovery
Avantor’s analyst price target has been reduced from $14.40 to $13.80 per share, as analysts cite ongoing operational headwinds and limited near-term earnings visibility following recent downgrades and mixed guidance. Analyst Commentary Recent analyst notes on Avantor capture a divided outlook, reflecting both positive updates from some firms and notable caution from others as the company contends with ongoing operational challenges.There's No Escaping Avantor, Inc.'s (NYSE:AVTR) Muted Earnings Despite A 28% Share Price Rise
Oct 28Pharma Contracts And R&D Will Drive Growth Amid Price Pressures
Analysts have modestly increased their price target for Avantor, raising it by $0.28 to $14.40. They cite revised expectations for end market recovery and alignment with company outlooks.We Think Avantor (NYSE:AVTR) Is Taking Some Risk With Its Debt
Sep 12Concerns Surrounding Avantor's (NYSE:AVTR) Performance
Aug 12What Is Avantor, Inc.'s (NYSE:AVTR) Share Price Doing?
Jun 26Earnings Working Against Avantor, Inc.'s (NYSE:AVTR) Share Price
May 14Avantor: A Healthier Diagnosis As Expectations Cool
Apr 26Avantor: Mundane Business, Solid Cash Flow, Potential New Risks
Mar 07Avantor: Durable FCF Generator Trading For Cheap
Dec 18Avantor: Uninspiring, Even Amidst Some Green Shoots
Oct 24
New Operating Model And Bioprocessing Innovations Promise Robust Growth And Market Leadership
Implementation of a new operating model and ongoing cost transformation initiatives are streamlining execution and improving net margins through cost savings.Avantor: Yet To Evidence Economic Value For Valuation Repricing, Reiterate Hold
Aug 13Ripartizione dei ricavi e delle spese
Come Avantor guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 26 | 6,552 | -551 | 1,571 | 0 |
| 31 Dec 25 | 6,552 | -530 | 1,574 | 0 |
| 30 Sep 25 | 6,575 | -82 | 1,506 | 0 |
| 30 Jun 25 | 6,666 | 687 | 1,556 | 0 |
| 31 Mar 25 | 6,685 | 716 | 1,535 | 0 |
| 31 Dec 24 | 6,784 | 712 | 1,554 | 0 |
| 30 Sep 24 | 6,820 | 310 | 1,616 | 0 |
| 30 Jun 24 | 6,826 | 360 | 1,545 | 0 |
| 31 Mar 24 | 6,867 | 260 | 1,497 | 0 |
| 31 Dec 23 | 6,967 | 321 | 1,466 | 0 |
| 30 Sep 23 | 7,039 | 364 | 1,470 | 0 |
| 30 Jun 23 | 7,176 | 423 | 1,475 | 0 |
| 31 Mar 23 | 7,342 | 610 | 1,469 | 0 |
| 31 Dec 22 | 7,512 | 662 | 1,452 | 0 |
| 30 Sep 22 | 7,625 | 598 | 1,442 | 0 |
| 30 Jun 22 | 7,603 | 572 | 1,445 | 0 |
| 31 Mar 22 | 7,551 | 534 | 1,463 | 0 |
| 31 Dec 21 | 7,386 | 508 | 1,426 | 0 |
| 30 Sep 21 | 7,269 | 466 | 1,442 | 0 |
| 30 Jun 21 | 7,040 | 267 | 1,388 | 0 |
| 31 Mar 21 | 6,660 | 169 | 1,345 | 0 |
| 31 Dec 20 | 6,394 | 52 | 1,342 | 0 |
| 30 Sep 20 | 6,127 | 71 | 1,336 | 0 |
| 30 Jun 20 | 6,026 | 135 | 1,332 | 0 |
| 31 Mar 20 | 6,079 | -226 | 1,334 | 0 |
| 31 Dec 19 | 6,040 | -335 | 1,329 | 0 |
| 30 Sep 19 | 5,990 | -514 | 1,294 | 0 |
| 30 Jun 19 | 5,981 | -554 | 1,303 | 0 |
| 31 Mar 19 | 5,926 | -330 | 1,305 | 0 |
| 31 Dec 18 | 5,864 | -356 | 1,321 | 0 |
| 30 Sep 18 | 5,120 | -639 | 1,215 | 0 |
| 31 Dec 17 | 1,247 | -415 | 376 | 0 |
| 31 Dec 16 | 691 | -42 | 257 | 0 |
| 31 Dec 15 | 637 | 22 | 185 | 0 |
Guadagni di qualità: AVTR al momento non è redditizia.
Margine di profitto in crescita: AVTR al momento non è redditizia.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: AVTR non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 20.9% all'anno.
Accelerare la crescita: Impossibile confrontare la crescita degli utili di AVTR nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia
Guadagni vs Settore: AVTR non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Life Sciences ( 2.5% ).
Rendimento del capitale proprio
ROE elevato: AVTR ha un Return on Equity negativo ( -9.87% ), in quanto al momento non è redditizio.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/04 13:32 |
| Prezzo dell'azione a fine giornata | 2026/05/04 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Avantor, Inc. è coperta da 29 analisti. 14 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |